Upbeat Aspen once again eyeing acquisitions
Pharmaceutical manufacturer was among many companies that sought to preserve cash amid Covid-19
14 March 2021 - 18:16
UPDATED 15 March 2021 - 07:20
SA’s biggest pharmaceutical manufacturer, Aspen Pharmacare, is optimistic it can achieve double-digit operating profit growth over the next three years, and is considering adding additional assets to leverage the benefits of a torturous acquisition and build programme.
Aspen was among a host of companies that scrapped dividends in 2020 as it sought to preserve cash amid the uncertainty created by Covid-19, while hefty debt levels weighed on its market value and forced it to sell off assets recently...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.